Emerging role of Jumonji domain-containing protein D3 in inflammatory diseases.
Histone demethylation
Inflammation
Inhibitor
JMJD3
Journal
Journal of pharmaceutical analysis
ISSN: 2214-0883
Titre abrégé: J Pharm Anal
Pays: China
ID NLM: 101579451
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
received:
18
12
2023
revised:
10
04
2024
accepted:
15
04
2024
medline:
24
9
2024
pubmed:
24
9
2024
entrez:
24
9
2024
Statut:
ppublish
Résumé
Jumonji domain-containing protein D3 (JMJD3) is a 2-oxoglutarate-dependent dioxygenase that specifically removes transcriptional repression marks di- and tri-methylated groups from lysine 27 on histone 3 (H3K27me2/3). The erasure of these marks leads to the activation of some associated genes, thereby influencing various biological processes, such as development, differentiation, and immune response. However, comprehensive descriptions regarding the relationship between JMJD3 and inflammation are lacking. Here, we provide a comprehensive overview of JMJD3, including its structure, functions, and involvement in inflammatory pathways. In addition, we summarize the evidence supporting JMJD3's role in several inflammatory diseases, as well as the potential therapeutic applications of JMJD3 inhibitors. Additionally, we also discuss the challenges and opportunities associated with investigating the functions of JMJD3 and developing targeted inhibitors and propose feasible solutions to provide valuable insights into the functional exploration and discovery of potential drugs targeting JMJD3 for inflammatory diseases.
Identifiants
pubmed: 39315124
doi: 10.1016/j.jpha.2024.100978
pii: S2095-1779(24)00075-3
pmc: PMC11417268
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100978Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.